News

Media focus

Industry News

News

High-quality research helps consistency evaluation, and the cooperative enterprise MAH will catch up with the new round of collection after being newly approved

High-quality research helps consistency evaluation, and the cooperative enterprise MAH will catch up with the new round of collection after being newly approved

The dust of the seven batches of centralized procurement has not yet been settled. Centralized procurement at the national and local levels has become normalized, triggering the reshaping of the industry and earth-shaking changes in rules. If a company is not fully prepared, does not change, accept and learn, and fails to improve, update, expand product pipelines, and reserve superior products, it will be a matter of time before it falls behind.

19

2022

/

07

Announcement of application for Jiangsu Provincial Graduate Workstation in 2022

Announcement of application for Jiangsu Provincial Graduate Workstation in 2022

According to the requirements of the Jiangsu Provincial Department of Education and the Jiangsu Provincial Department of Science and Technology "Notice on Doing a Good job in Applying for the Jiangsu Provincial Graduate Workstation and the Jiangsu Provincial Excellent Postgraduate Workstation Demonstration Base in 2022" (Jiangsu Education Office Research Letter [2022] No. 2), our company's 2022 Preliminary application for the Jiangsu Provincial Graduate Workstation will be made jointly with China Pharmaceutical University. The relevant declaration information will now be made public.

14

2022

/

07

2020 New Year Speech

2020 New Year Speech

Since entering 2019 , the pharmaceutical industry has faced a series of pressures and challenges such as industrial upgrading, policy changes, increased requirements, price control, etc. Many peer companies have transformed. At the end of the year and the new year, people in Jiqun should sort out their moods and join hands with each other. , devote yourself to creation with fuller enthusiasm and realize the value of life!

19

2020

/

01

Leaders from the Municipal Science and Technology Bureau and Jiangning District Government visited our company for investigation and guidance

Leaders from the Municipal Science and Technology Bureau and Jiangning District Government visited our company for investigation and guidance

On December 15 , 2019 , Director Hong of the Nanjing Municipal Science and Technology Bureau led a team to investigate Nanjing Jiqun Pharmaceutical Technology Co., Ltd. to gain a detailed understanding of our company’s development and operations, and to coordinate and resolve the company’s development demands. District Mayor Miao of Jiangning District and other relevant responsible comrades Accompany the research. Our company’s Chairman Li Zhan, General Manager Huo Liru and other senior management teams, as well as heads of relevant departments, participated in the exchange meeting.

18

2019

/

12

Jiqun Pharmaceutical: GP-21401, a new insomnia drug, obtained phase II and III clinical trial approval

Jiqun Pharmaceutical: GP-21401, a new insomnia drug, obtained phase II and III clinical trial approval

The new product GP-21401 ( GP401 ) applied by Nanjing Jiqun Pharmaceutical Technology Co., Ltd. as a marketing authorization holder has recently obtained the "Clinical Trial Notification" (hereinafter referred to as "NMPA") issued by the National Medical Products Administration (hereinafter referred to as "NMPA" ). CYHS1900169 ), Phase II clinical trials will be launched soon!

18

2019

/

12

The new website of Jiqun Pharmaceutical is officially launched!

The new website of Jiqun Pharmaceutical is officially launched!

The new website of Jiqun Pharmaceutical is officially launched!

27

2018

/

06

The company received funding from the

The company received funding from the "Nanjing 321 Talent Plan"

On April 30, 2014, the company’s “phosphoramidite-based guanine nucleotide anti-hepatitis B drug JQ-301” project with independent property rights successfully passed the review and received funding from the 2013 Nanjing 321 Science and Technology Talent Program.

24

2018

/

05

The company undertakes various technical services, registration consulting and other services. Welcome to call us for discussion.

The company undertakes various technical services, registration consulting and other services. Welcome to call us for discussion.

The company has strong R&D capabilities and a complete set of disciplines. The synthesis, pharmacology, preparation, analysis and other departments are all equipped with experienced subject leaders, and the laboratory facilities are complete. The company has established a complete organizational management and project management system. Team members all have many years of experience in innovative drug research and development. They all have many years of work experience in large pharmaceutical research and development companies. They are familiar with innovative drug research and development and application processes, policies and regulations, and have strong collaboration capabilities.

24

2018

/

05

< 12 >